Novartis AG will acquire Avidity Biosciences, Inc. for $12B, aiming to strengthen its neuroscience franchise. Learn more ...
An international research team, led by Shinghua Ding at the University of Missouri, has identified a previously unknown ...
Immunosuppressive medications. Drugs like corticosteroids or azathioprine work by calming the immune system and reducing the ...
The Swiss drugmaker on Sunday said it agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion in cash ...
CAR-T therapies from Cabaletta Bio and Bristol Myers Squibb have induced complete remissions in patients living with a severe ...
New interim data from a Phase III trial puts the company on track to file for FDA approval next year in an indication that ...
According to the agreement, Avidity ( NASDAQ: RNA) shareholders will receive $72 a share in cash, a 46% premium to Friday’s ...
Circulating tumour DNA-guided adjuvant atezolizumab prolongs disease-free and overall survival in patients with ...
His parents Stephen and Jenny have asked Sheffield Children's NHS Foundation Trust to approve the use of drug givinostat, ...
BridgeBio Pharma said on Monday its experimental drug for a rare muscle disorder, which currently has no approved treatments, showed improvements in motor and lung function in a late-stage trial, ...
Novartis plans to acquire Avidity Biosciences to add RNA therapeutics to its neuroscience biz to target rare genetic ...
Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 3 study titled ‘A PHASE 3, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback